We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hamburg Defends Biosimilar Substitution, Says Efforts to Undermine Trust Are ‘Worrisome’
Hamburg Defends Biosimilar Substitution, Says Efforts to Undermine Trust Are ‘Worrisome’
February 22, 2013
ORLANDO — FDA Commissioner Margaret Hamburg defended the substitutability of interchangeable biosimilars, saying that attempts to undermine trust in the products are “worrisome and represent a disservice to patients who could benefit from these lower-cost treatments.”